IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.

Abstract excerpt

BACKGROUND: Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, successful targeting of the RAS gene remains a persistent challenge in the field of cancer therapy. In our study, we discover a promising avenue for addressing this challenge....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Survival
• Share to I-kappa B Kinase
• Share to NF-KappaB Inhibitor alpha